Brainstorm Cell Therapeutics Inc. announced as part of this strategic realignment, Dr. Kirk Taylor, EVP and Chief Medical Officer, will be stepping down from his post, which largely focused on leading global medical affairs and broader launch activities. Certain other positions that are outside the current prioritized scope will be eliminated.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5345 USD | +0.47% | +0.47% | +95.79% |
Apr. 17 | Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024 | CI |
Apr. 17 | Brainstorm Cell Therapeutics Inc. Announces Management Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+95.79% | 36.53M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- BCLI Stock
- News Brainstorm Cell Therapeutics Inc.
- Brainstorm Cell Therapeutics Inc. Announces Resignation of Dr. Kirk Taylor as EVP and Chief Medical Officer